



**ASAM** The Voice of Addiction Medicine  
American Society of Addiction Medicine

## Medicaid Coverage of Medications for the Treatment of Opioid Use Disorder

In Indiana between 2008-2012, persons enrolled in substance use treatment programs that prescribed methadone increased **5.3%**. In 2012 in Indiana, **13.7%** of persons aged 12 and older who met criteria for having a drug use disorder received treatment<sup>α</sup>.

**INDIANA**

### State Benefits at a Glance<sup>β</sup>...

#### Methadone

Indiana Medicaid covers methadone under Managed Care (MC) plans only. In order to receive coverage for methadone used for the treatment of opioid use disorder, federal law mandates that patients are enrolled in, or have documented proof of, substance use disorder (SUD) counseling.

#### **Buprenorphine/Naloxone film (Suboxone<sup>®</sup>), Buprenorphine/Naloxone tablets (generic), Buprenorphine/Naloxone tablets (Zubsolv<sup>®c</sup>) and Buprenorphine tablets (generic).**

##### Medication Limitations

Indiana Medicaid covers Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets under Fee-For-Service (FFS) and MC plans with the following limitations:

- In order to approve these medications for the treatment of opioid use disorder, patients must be enrolled in, or have documented proof of, SUD\* counseling.
- A patient must be 16 years or older to use any of these medications.
- Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets are authorized for use during pregnancy.
- Buprenorphine/naloxone tablets are subject to step therapy. A patient must first be unsuccessful with oral film.
- Buprenorphine tablets carry a duration limit of 34 days.
- Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets require prior authorization for use.
- Zubsolv appears on Indiana Medicaid's Non-Preferred Drug List.
- In most cases, Zubsolv is subject to the same prior authorization requirements as the surveyed buprenorphine products.

Indiana covers all medications as a pharmacy benefit under both FFS and MC plans. Suboxone and buprenorphine tablets are listed on Indiana's preferred drug list for FFS and MC plans; buprenorphine/naloxone tablets are not. All medications are covered for use in organized specialty outpatient treatment programs (OTPs), accredited outpatient narcotic treatment programs (NTPs) and physician's offices under FFS and MC plans.



## State Benefits at a Glance (continued)...

### Injectable Naltrexone (VIVITROL®)

Indiana Medicaid covers injectable naltrexone (Vivitrol®) under both FFS and MC plans. Patients **must** be enrolled in, or have documented proof of, SUD\* counseling for Vivitrol coverage.

- Vivitrol is covered as a both a medical and a pharmacy benefit under FFS and MC plans.
- Prior authorization is required for use.
- Vivitrol does not appear on Indiana’s preferred drug list under FFS or MC plans.

Vivitrol is covered for use in OTPs, NTPs and physician’s offices under both FFS and MC plans.

<sup>a</sup> Data from SAMHSA’s State and Metro Reports accessed [http://www.samhsa.gov/data/States\\_In\\_Brief\\_Reports.aspx](http://www.samhsa.gov/data/States_In_Brief_Reports.aspx)

<sup>b</sup> Data as of spring 2014.

<sup>c</sup> Zubsolv was not included in the original survey, as the medication was not FDA approved until fall of 2013. This summary reflects only information related to Preferred Drug List (PDL) and formulary inclusion obtained from pharmacy and State websites.

\*In Indiana, substance Use Disorder (SUD) counseling is a covered Medicaid benefit under FFS and MC plans.

## Medicaid Benefits for Treatment of Opioid Dependence Nationwide

Number of Medications Covered under Fee-For-Service Medicaid Plans By State

